Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 16, 2022
In 2020, we opened our end-of-year review by saying that “Not even Dr. Pangloss could put a positive spin on… a historic dumpster fire of a year.” The next year, we described 2021 as “not quite the best of times, not quite the worst of times”, which seemed like progress. But if we take one lesson fr...
CGD NOTES
December 14, 2022
Ensuring rapid and equitable access to effective oral COVID-19 therapies is essential to reducing health disparities from COVID-19 and building a better response system for future epidemics and pandemics. A multipronged strategy for medical countermeasures must include antivirals, monoclonal antibod...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
December 09, 2022
Mitchell faces a very difficult task. It will help him enormously that he has a clear-eyed sense of the problems he faces and the scale of the challenge. But to reverse them will take decisive action, with support from elsewhere in Whitehall, too. Our note suggests one way to do so.
CGD NOTES
December 09, 2022
There is a very real possibility that the UK ceases to be a significant presence in international development over the next couple of years; indeed, this is the most likely outcome at present. In this note, we set out the challenges facing Mitchell, and how each of our recommendations can be achieve...
BRIEFS
December 08, 2022
Drug-resistant infections kill an estimated 7,600 UK citizens every year. Without investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from an expanded prog...
Blog Post
December 02, 2022
An important debate is taking place in Europe right now on how to fund new antimicrobials. For months it has been speculated that the European Union may move towards implementing transferable exclusivity vouchers (TEVs). In response, 14 Member States wrote to the European Commission outlining why th...
Blog Post
November 15, 2022
Congress has excellent legislation on the docket that would protect American citizens, yield huge returns, and create a safer, healthier world. We encourage the US Congress to urgently finance and authorize the PASTEUR Act, leveraging American ingenuity to boost our shared health future.